ReviewCurrent cardiology reports2019
Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.
Review in Current cardiology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Development and validation of a novel diagnostic nomogram model to predict primary aldosteronism in patients with hypertension.Endocrine · 2021Trial
- Primary aldosteronism.Nature reviews. Disease primers · 2026Review
- Primary Aldosteronism Causing Aortic Dissection: A Case Report.The American journal of case reports · 2026Article
- Primary aldosteronism: adrenalectomy could save more lives.Frontiers in endocrinology · 2025Review
- Sodium Chloride Cotransporter in Hypertension.Biomedicines · 2024Review
- Hyperaldosteronism Screening and Findings From a Large Diverse Population With Resistant Hypertension Within an Integrated Health System.The Permanente journal · 2024Article
- Dietary sodium alters aldosterone's effect on renal sodium transporter expression and distal convoluted tubule remodelling.The Journal of physiology · 2024Article
- Primary Aldosteronism in Chronic Kidney Disease: Blood Pressure Control and Kidney and Cardiovascular Outcomes After Surgical Versus Medical Management.Hypertension (Dallas, Tex. : 1979) · 2023Article
- Article
- Lateralization inEndocrinology, diabetes & metabolism · 2022Article
- High Prevalence of Autonomous Aldosterone Production in Hypertension: How to Identify and Treat It.Current hypertension reports · 2022Review
- Re-Assessment of the Oral Salt Loading Test Using a New Chemiluminescent Enzyme Immunoassay Based on a Two-Step Sandwich Method to Measure 24-Hour Urine Aldosterone Excretion.Frontiers in endocrinology · 2022Article
- Screening for Primary Aldosteronism is Underutilized in Patients with Obstructive Sleep Apnea.The American journal of medicine · 2022Article
- Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving.Surgery · 2022Article
- Approach to the diagnosis of secondary hypertension in adults.Australian prescriber · 2021Review
- Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism.Endocrine · 2021Article
- Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism.European journal of endocrinology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPrimary aldosteronism (PA) is a common form of hypertension characterized by autonomous aldosterone secretion from one or both adrenal glands. The purpose of this review is to synthesize recent research findings regarding cardiovascular disease risk in PA both pre- and post-targeted therapy. RECENT
findingsPreviously considered a rare disease, recent prevalence studies demonstrate that PA is actually a very common, yet vastly under-diagnosed, etiology of hypertension. Prior to targeted therapy, PA is associated with substantially higher rates of cardiovascular disease compared with essential hypertension. Surgical adrenalectomy is highly effective in curing or improving hypertension as well as mitigating cardiovascular disease risk in patients with unilateral PA. For the remainder of PA patients, MR antagonists are recommended; however, several recent studies have brought into question their effectiveness in improving cardiovascular outcomes. PA is a common cause of hypertension that leads to disproportionately high rates of cardiovascular disease. Future studies are needed to enhance the clinical approach to both identification and treatment of patients with PA to optimize long-term cardiovascular outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.